Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CAMP4 Therapeutics Corporation filings document a clinical-stage biopharmaceutical issuer focused on regulatory RNA-targeting antisense oligonucleotide therapeutics. Its 8-K reports furnish operating results, corporate presentations and program updates for CMP-002 and the company's broader regRNA mapping and ASO discovery work, while material-agreement disclosures describe research, collaboration and license arrangements tied to neurodegenerative and kidney disease targets.
Proxy materials cover board elections, auditor ratification and equity incentive plan matters. Other filings address director appointments, compensatory arrangements, stock-based compensation, capital-structure disclosures, shareholder voting matters and the company’s emerging growth company status.
Camp4 Therapeutics Corp. (CAMP) – Form 4 insider transaction
Director and 10% owner Andrew J. Schwab reported the grant of 9,000 non-qualified stock options on 25 June 2025. The options carry an exercise price of $1.56 per share and expire on 24 June 2035, providing a 10-year term.
- Vesting: The entire award vests on the earlier of (i) the first anniversary of the grant date or (ii) the next annual meeting of stockholders, subject to Mr. Schwab’s continued board service.
- Ownership status: All 9,000 options are held directly by the reporting person; the filing shows no prior derivative holdings, so the post-grant balance is 9,000 options.
- Transaction code “A” denotes an award rather than an open-market purchase or sale; no cash consideration was paid for the grant (price indicated as $0).
The filing does not disclose any accompanying sales or acquisitions of common shares, nor does it provide earnings or operational data. As such, the Form 4 primarily signals continued equity-based incentive alignment between the director/large shareholder and outside investors.
Camp4 Therapeutics Corp. (CAMP) filed a Form 4 disclosing a routine equity compensation grant to director and 10% owner Amir Nashat. On 06/25/2025 Nashat received 9,000 non-qualified stock options with an exercise price of $1.56 per share. All options vest on the earlier of (i) the first anniversary of the grant or (ii) the company’s next annual shareholder meeting, provided Nashat continues to serve on the board through that date. The options carry a 10-year term expiring 06/24/2035 and were reported as direct beneficial ownership. No shares of common stock were bought or sold; the filing reflects only the grant of derivative securities. The size of the award is modest and does not materially change the company’s share count or insider ownership profile.